Barclays analyst Carter Gould raised the firm’s price target on Eli Lilly to $400 from $395 and keeps an Overweight rating on the shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- ProQR Therapeutics price target raised to $5 from $2 at Raymond James
- ProQR Therapeutics shares remain ‘fairly valued,’ says JMP Securities
- PRQR Skyrockets Following Expanded Collaboration with LLY
- Eli Lilly, ProQR expand genetic medicines licensing and collaboration agreement
- Eli Lilly, ProQR Therapeutics to expand RNA editing collaboration